Altair
Skip to content

Trading Analysis Report: ADBE

Analysis date: 2026-10-14 · Model: claude-opus-5-5 · AI-generated, not financial advice.

  • Analysis date: 2026-10-14
  • Rating: Underweight
  • Generated: 2026-10-15 00:20:27
  • TradingAgents 0.6.0: anthropic, deep claude-opus-5-5, quick claude-sonnet-5-5
  • Analysts: market, sentiment, news, fundamentals; research debate rounds 5, risk debate rounds 5
  • Data vendors: core_stock_apis yfinance, technical_indicators yfinance, fundamental_data sec_edgar,yfinance, news_data yfinance, macro_data fred, prediction_markets polymarket

V. Portfolio Manager Decision

Rating: Underweight

Executive Summary: Underweight ADBE. Existing holders should trim in stages, not exit. Do not initiate or chase a breakout, and do not short. All rungs below are ceilings in percent of a standard position: sell about 10 points now; go to 75-80 into 244-246; go to 60 at 248-251; go to about 45 on a rejection back under 250 after a test of 255-257; make one cut to 30 on a close below 227 (market-on-close sent by 3:50) or a stop-market near 222, written as 'sell down to 30' with each order cancelling the other; and go into the mid-December Q4 print at 40 or less until the Q3 10-Q is read. Before each event (FOMC, Oct 31, Nov 3, any Adobe event, the print), size the position you actually hold so a 20% shock to about 190 stays within your single-name loss limit (about 1% of the book). If it fails that test, sell to the passing weight today at market. Horizon is about 2-3 months, through the Q4 print.

Current Price: 240.68

Price Target: 239.0

Confidence: Medium

Time Horizon: 2-3 months

IV. Risk Management Team Decision

Aggressive Analyst

Aggressive Analyst: Since neither of you has spoken yet, I'll set the terms and answer the objections I expect.

The easy, popular trade here is buying the dip. ADBE is about 33% off its October high, trades at 13x GAAP earnings with a 10-11% free cash flow yield, and StockTwits is tagging bullish. The bolder call is to act on what's in the numbers before confirmation arrives. In Q3, revenue grew about $772M year over year and operating income grew about $181M. Only 23 cents of each new revenue dollar reached operating income, at a company that runs 35% margins. Gross margin has slipped from 89.6 to 89.2 to 88.7 across three quarters, and cost of revenue growth has accelerated from 6.8% to 12.1% to 18.8%. We don't know why. AI delivery cost is a hypothesis, not a finding. But the direction matches the bear thesis: growth that is getting more expensive to produce. Net income grew 3%, and EPS grew 10.5% mostly because the share count fell about 7%. Buybacks are carrying the headline.

To the "it's cheap" crowd: the sub-10x and 8.75x figures are forward and likely non-GAAP. On GAAP numbers it's 13 to 14x, and a low multiple isn't a floor in a sector where estimates are being questioned. The macro also works against software multiples. Polymarket has a 97% chance of no cuts this year and 82% on another hike, and hot inflation is pushing yields up. With a beta of 1.4, that is a poor backdrop for paying up for a 3% net income grower. A flat-multiple target near 265 is only about 3% above the 257 resistance cluster, so the upside for a breakout buy is thin.

On the technicals, the bounce is real but unconvincing. Today's 3.48M shares compares with a 4.2M ten-day average, while the breaks down came on 17M and 25M. Sellers showed up with conviction, and buyers haven't yet. OBV is still near its lows, and the 50/200 "golden cross" is cosmetic, because the 200 SMA fell into price while the 50 is rolling over. Price is 6% below both averages, and the daily SuperTrend stop sits right in that cluster. Selling a third at 248-251 and the rest at 255-257 means selling into a stack of resistance, not panicking at the low.

I'll rebut the neutral view first, since I expect "it's range-bound, weekly trend is up, just hold." The range is roughly 228 to 250, and holding a full position through the middle of it earns nothing for the risk. Selling at the top of the range is better risk-reward. From 250, the stop at 227 is about 9% away, the weekly SuperTrend at 206 is about 18% away, and the realistic upside to 265 is about 6%, through resistance. That isn't lopsided, which is why I call it a trim and not a thesis. I'm also not ignoring the weekly uptrend. Keeping 50-60% of a standard allocation is how we respect it. The residual is our call option on a daily flip above 257, and we hold it with the weekly stop at 206 as the hard exit.

To the conservative view, I expect "exit entirely, the balance sheet is thin and the Fed is hawkish." I disagree. Revenue growth is accelerating to nearly 13%, FCF margins are around 36-41%, and the 0.77 current ratio is normal for a subscription business throwing off roughly $10B a year. Nothing in the data shows revenue or cash flow breaking. A director also bought $1.95M at $194.51 in June. That buy came about 20% below today's price, so it doesn't tell us much about 240, but it argues against treating this as broken. A full exit or a short would be a bet on a break that the evidence doesn't show. The CEO's $18M sale in April, near today's price, is a mild yellow flag and nothing more.

What does the trim cost if we're wrong? If the daily SuperTrend flips and the stock runs back toward the August peak near 293, we give up roughly 15% on the slice we sold. I accept that. The sizing rule caps the residual so a gap to 200 costs about 1% of the portfolio, which works out to a position of roughly 5 to 6% of the book. We keep real upside, we put a hard number on the downside, and the proceeds go to opportunities with better asymmetry.

I also want to be honest about the gaps. We don't have the Q3 10-Q, consensus numbers, or options data. That's why conviction is moderate and why the plan is a trim with defined triggers. If ADBE closes above 257 on volume with RSI above 50, the facts change and I'd revisit the plan. If it closes below 227 on volume above 4.2M, we finish the trim at market. Until then, selling into the bounce on rising incremental costs and a thin-volume rally is the right call.

FINAL TRANSACTION PROPOSAL: SELL Aggressive Analyst: You two ended up closer to my plan than your opening lines suggest, so I'll say where you moved me and then where I'm holding.

Where you're right

Conservative, the 255-257 limit orders were a hope. My own trigger says a close above 257 with RSI over 50 changes the facts, so Neutral's framing is more coherent: treat that cluster as a test. Sell on a rejection back under 250 and rebuild on a confirmed close above. I'm adopting that.

I'm also dropping "call option." A call has a capped loss and my residual doesn't. 206 is a catastrophe backstop. The residual's real exits are the ones Neutral laid out, about 40% on a volume close under 227 and a quarter or less under 224.67. That makes the 227 trigger the first cut, not the last step of the trim.

Conservative's cost arithmetic checks. Of the 23 cents that reach operating income per new revenue dollar, about 16 cents of the missing 77 is cost of revenue and about 61 cents is operating expense, which grew roughly 15% against 12.9% revenue growth. AI delivery explains under half of the problem.

Neutral is also right that operating expense is discretionary. If December shows opex growth converging toward revenue growth, 23 cents becomes 35 and my thesis is wrong. That is what I'm watching.

Three smaller concessions: - Net income at +3% was the framing that suited me. Operating income is +8% and nine-month free cash flow is +11%. Both still trail revenue, but neither is "a 3% grower." - Today's volume is 17% under average, which is soft, not thin. I'll call the bounce unconfirmed, not unconvincing. - The 10-Q is public. Its absence from my data is a tool gap, not a reason to size down, so I'd read it before the second tranche. - I named no better-asymmetry idea for the proceeds, so they default to cash or short paper.

Where I hold, against Conservative

Selling a big block at 240.68 gives away the middle of the range. The stock just absorbed a downgrade, a hot inflation week and a $236 close, and held 231 to 242. Here's the odds math. 250 is 3.9% away and 227 is 5.7% away, so in a flat range the stock is about 60/40 to tag 250 first. That makes waiting versus selling now roughly a wash in expectation. The edge isn't in timing, it's in conviction, and mine is moderate. That justifies a modest early tranche, not a large one.

"If it rolls over we've sold nothing" is true, but the cost is bounded at about 5.7% to the 227 trigger on the unsold slice. The 14-18% to 206 only applies to what's left after the trim is complete.

Sizing the residual to 2-2.5% so that a trip to 190 costs half a percent double-counts, because that loss is what the exits at 224-227 exist to prevent. Neutral has this right: fix the exit, don't shrink the position. Whether the loss budget is 0.5% or 1% is the caller's choice, and Neutral's stress test (residual weight times about 20%) lets them pick.

Neutral's point also cuts against a heavy sale now. A stock that rose 51% in two months can do it again on a daily flip. If we're down to 25% at 240, we own nothing in that case.

Where I hold, against Neutral

I'd make the first rung smaller. Going to about 85-90% in the 242-246 zone is insurance, and 75% overpays for it. The real sale zone is 248-251. It sits at the upper Bollinger band (250.74), about one ATR away, and just above the 248.3 tag from October 1. Go to roughly 60% there, then about 50% on a rejection at 255-257.

I'd also add one rule you didn't. If the position is still above about 60% as the December print approaches (expected mid-December, unconfirmed), sell down to 60% before the report. The two big-volume breaks in the data look like earnings reactions, as Neutral says. If so, the market has sold off on exactly the margin story I'm worried about. A thesis that says costs are outrunning revenue shouldn't go into a print at full size.

Macro and valuation

You're both right that 97% no cuts is priced in. I'm not selling on the Fed. I'm selling on incremental margins, and I'd use beta only through the stress formula.

On valuation, 13x GAAP with roughly 8% free cash flow yield after a stock comp haircut isn't expensive. But a cheap multiple isn't a catalyst either. HSBC's Hold carries a $267 target, 11% above here, so the street hasn't capitulated yet. If targets get cut toward the price, that's a headwind, though that's my inference.

The bold part of this call was never the size of the trim. It's selling what the crowd calls cheap while it's holding up, because the cost structure says growth is getting more expensive. The retail bull case is seven labeled bulls against two, from five authors, mostly echoing the "under 10x" headlines, which are forward and probably non-GAAP.

The plan, in percent of a full position

  • 242-246: about 85-90%.
  • 248-251: about 60%.
  • Rejection at 255-257: about 50%.
  • Close above 257 with RSI over 50 and better volume: hold, and consider rebuilding.
  • Volume close below 227: about 40%.
  • Close below 224.67: a quarter or less, with the weekly 206 as the last line.
  • Sized for the December print: 60% or less going in.

If you hold nothing, don't initiate.

FINAL TRANSACTION PROPOSAL: SELL Aggressive Analyst: Neutral did the most useful thing in this debate, which was to price the disagreement. I reran it and it holds. On a twenty-point slice, selling at 240.68 instead of 250 costs about three-quarters of a point if the stock rallies, and saves a bit over a point if 227 breaks first. At 60/40 that nets to nothing. So I'm done fighting over the first rung, and I'll say where I'm moving and where I'm still holding.

Conservative, you caught a real contradiction. I said that at 25% we'd own nothing if the stock ran again, but my own rule rebuilds above 257. Buying back at 258 after selling at 240 costs about 7% on the slice. That's a bounded price, and I shouldn't have called it a disaster. You're also right that a limit resting at 242-246 is a hope, because the stock hasn't closed above 242.27 since the September low. So I'll sell about ten points now and ten more into 244-246, which gets us to roughly 80.

You're right on the 227 and 224.67 cuts as well. They're 2.33 apart and fire together on any gap, so it's one cut, to about 30. The table shows nothing between 224.67 and 206, and that air pocket is why it should be one decisive cut. Your "226 close, 219 open" scenario is a procedure problem, not a sizing problem. A close-based trigger doesn't have to wait for the next morning. If the stock is under 227 on heavy volume in the last fifteen minutes, sell then. A heavy-volume trade through 224.67 is also a sale no matter where it closes.

Neutral is right that I can't call December a test of my thesis and then carry 60% into it. I'm coming down to 50.

Here is where I'm holding. On variance as a tiebreaker, Neutral's answer works for me. Variance is always lowest in cash, so it can't decide how much to hold. We've already spent most of the variance budget by agreeing to carry 40 to 50 fewer points than a full position. As for 40 versus 50 into the print, that's ten points times a roughly 7% gap, under a point. The gap can also go up, since a 13x GAAP stock that shows opex growth converging toward revenue growth won't gap down. I'll tie that last ten points to the 10-Q, which brings me to Neutral's best point.

Neutral, the $126M between operating income and net income is bigger than the gross margin story. Operating income grew $181M and net income grew $55M. Falling interest income explains only part of it, since cash is down about $3B from November 2024 and at plausible yields that's tens of millions a quarter, not $126M. It also means I shouldn't lean on "net income +3%" at all. My thesis lives on the operating line, where only 23 cents of each new revenue dollar arrived in Q3 and about 26 cents over nine months.

Here's something I checked that nobody has raised. The nine-month cash walk ties out: operating cash flow of 7,646, less investing of 1,910, less financing of 6,810, is about −1,074, against a reported cash change of −1,072. So the $1.9B investing outflow is real cash going out the door. From memory, and unverified because our data doesn't say, Adobe announced a cash acquisition of Semrush for about $1.9B in late 2025. If that closed in the first half, it could explain a lot of what we've called unexplained. It would account for gross margin slipping each quarter, cost of revenue growth accelerating, opex outrunning revenue, lower interest income, and part of the "accelerating" revenue being bought, not organic.

That cuts both ways. If it's an acquisition, my "costs are outrunning revenue" story is weaker, and so is the bulls' "growth is accelerating" story. This is why conviction stays moderate, and why the 10-Q read happens before the second rung, not after. If the squeeze is acquisition noise, I hold 50 into December. If it's organic, I go to 40 and Conservative gets his number.

I'm still not selling on macro. The hike market is $0.78M deep and I wouldn't size anything off a five-point move in it. I'll run the stress test, residual weight times about 20%, before each event: the late-October FOMC once the date is confirmed, the November 3 midterms, and the print.

In percent of a full position, the plan is this. Sell ten now, then ten more into 244-246, to about 80. Go to 60 at 248-251. On a rejection back under 250 after tagging 255-257, go to 50. A close above 257 with RSI over 50 and better volume means hold and rebuild in steps, but only toward 75-80, because the monthly trend is still down. One cut to about 30 on a heavy-volume close under 227, or a heavy-volume trade through 224.67, with the weekly 206 as the last line for a small core. Go into December at 50, or 40 if the filing says the squeeze is organic. Proceeds sit in cash or short paper until someone names a better idea. If you hold nothing, don't initiate.

This is still the aggressive call. The crowd is buying a "cheap" stock, and we're committing to a specific falsifier, opex growth converging in December, while keeping real exposure to a daily trend flip.

FINAL TRANSACTION PROPOSAL: SELL Aggressive Analyst: Neutral, Conservative, we've converged enough that I'd rather list what's settled and then argue the three things that aren't. Settled: sell ten now, ten more into 244 to 246, go to sixty at 248 to 251 and about forty-five on a rejection at 255 to 257, make one cut to about thirty on a break, go into December at fifty or less, hold proceeds in cash, and don't initiate if you hold nothing. Those are Neutral's numbers and nearly mine, and the gap to Conservative's is about a point of position value.

Conservative first. You're right that percent of a full position isn't a risk number, and the trader's plan already contains your formula. It says to size the residual so a gap to about 200 costs one percent of the book. That's a 17 percent move from here, which is where the five-to-six percent of the book came from. So I take your override as written: residual weight times the shock, checked against the loss limit, and the lower number wins. Neutral's two shocks work for me, about 20 percent for a slide through the exits and about 12 percent for a print. At a one percent limit, that allows roughly 5 percent of the book going through the exits and 8 percent going into the report. Run it before the FOMC, the midterms and the print, and cut only if it fails. I wouldn't cut pre-emptively for events where my thesis has nothing scheduled to resolve. It resolves in December, and everything before that is price.

You also made the best point about the ladder: it sells strength, and the risk sits in the branch with no strength. That's why I'm selling ten now instead of leaving it all to resting orders. Beyond that, Neutral priced the first rung at about half a point either way, and I'm not going to fight over it.

On Semrush, let me put numbers on how it cuts. If the deal adds a few hundred million a year in revenue, that's $75 to $100 million a quarter, or roughly 1.1 to 1.5 points on a $6.76 billion quarter. If it was in for most of Q2 and Q3, organic growth in Q3 would be near 11.5 percent, below Q1's 12.0 percent. Neutral is right that Q1 already beat last year's 10.5 percent before any deal, but the reading would then be no further acceleration and maybe a dip. That's the number to pull from the filing. I agree with reading it today, not before the second rung. It moves the December weight, not today's trade.

Neutral, three things. On the close-based trigger with no volume filter, I'll take it, and it's safer than I feared. The lowest close of the whole consolidation is 231.01, so a close below 227 is a new closing low by 1.7 percent. September 28's wick, which printed 224.67 and closed at 231.01, never trips it. But your backstop just under 224 sits 67 cents below that same wick, less than a tenth of an ATR. A wick one point deeper sells the low, and then the stock closes back above 230. That order exists only for the day with no close to act on, so I'd put it about a third of an ATR under the swing low, around 222.

On rebuilding, a daily SuperTrend flip plus a close above both averages is the right trigger. Thanks for catching September 14: 265.6 was under the 200 SMA at 266.34, so that rule would not have fired, and it wouldn't have bought the failure. Where I part ways is waiting for a retest before buying anything. The summer move was 193 to 293 in about two months, and V-shaped moves don't always hand out retests. I'd buy the first third on the flip-close, the second on a retest that holds, and the third on weekly follow-through, capped at 75 to 80. A failed first third costs about a point of position value. Missing the first leg of a 50 percent move costs more. Reset the levels weekly, since the 200 SMA is drifting down into the second rung.

On December, you're right that my falsifier was too narrow. Opex growth converging is necessary but not sufficient. If the guide comes with the report, as you recall but haven't confirmed, I want opex converging and a guide that doesn't price in another year of margin compression. Otherwise I'm wrong in one direction and still lose in the other.

This is still the bold call. The retail tape is tagging a 13x stock bullish right after a downgrade, and the numbers say cheapness isn't a catalyst when only 23 cents of each new revenue dollar reaches operating income. We're selling into a thin-volume bounce against that crowd without waiting for estimates to break. But we do it with a named falsifier, mechanical exits and a rebuild trigger, so if the daily trend flips we're back in size. What we give up if wrong is bounded at a point or two of position value. What we avoid is a 17 to 20 percent slide through a thin stretch of the chart between 224.67 and 206, on a stock that has already shown two 7 percent single-day breaks.

Here's the plan in percent of a full position. Every number is a ceiling, so if you're already below a rung you neither sell more nor buy.

Sell about ten now and ten more into 244 to 246, landing at 75 to 80. Go to about 60 at 248 to 251. Go to about 45 on a rejection back under 250 after a test of 255 to 257. Make one cut to about 30 on a close below 227 with a market-on-close order, or on a trade through about 222 as the backstop. Rebuild in thirds as described, capped at 75 to 80. Go into the December report at 50 or less, or 40 if the 10-Q says the squeeze is organic or the loss formula doesn't clear. Run the residual-weight stress before the FOMC once the date is confirmed, before November 3, and before the print. Proceeds stay in cash or short paper, because I still haven't named a better use. I don't know the caller's book, so the loss-limit formula decides the final number. If you hold nothing, don't initiate.

FINAL TRANSACTION PROPOSAL: SELL Aggressive Analyst: Most of the plan is settled. All three of us sell about ten points now and ten more into 244 to 246. We go to 60 at 248 to 251 and to about 45 on a rejection at 255 to 257. One cut to about 30 comes on a sub-227 close at the 3:50 check, with a stop-market near 222 behind it. We rebuild in thirds capped at 75 to 80, go into December at 50 or less, and don't initiate if you hold nothing. What's left is a few arguments about how much insurance to buy, so I'll take them in turn.

Neutral, you're right on two things. First, I priced this as a point or two of position value, and that was only the first rung. If the stock runs straight to 293, the whole ladder misses about five points after the rebuild claws some back, and the break branch costs about the same. It isn't a cheap option and I shouldn't have sold it as one. Second, selling after a downgrade into down daily and monthly trends goes with the news flow. What I'm leaning against is the valuation crowd: seven-to-two tags from five authors repeating the under-10x headline. That's too thin to borrow confidence from. Mine comes from 23 cents of incremental margin, a cost of revenue line that has accelerated three quarters running, and a named December falsifier, and it's moderate.

Conservative, you said that when the exits work the two branches cost the same, so the asymmetry lives in the gap case and argues for carrying less. I agree the tail is the point. But the loss-limit formula caps exactly that tail, and you've accepted it as the override. If a gap to 200 costs no more than 1% of the book at the weight the caller holds, the tail is already priced in dollars they chose. A lower December number, a heavier print shock and extra selling mid-range are a second premium on bounded risk.

I'll take your best point, though. The formula has to run on the weight held today, not the residual. The ladder sells strength, so in the straight-down branch you're still at 85 or 90 when things break. If that weight fails the test, sell to the passing weight today at market and don't wait for 246. I won't add a number on top of the caller's own limit.

On print stress, I'll take 15%, because it costs nothing. A 1% limit against a 17% move to 200 allows about 5.9% of the book, and against 15% it allows 6.7%. The standing test binds first, so the print number never gets used. The exit budget is similar: 225 if someone is there at 3:50, 222 if not. I'd add one operational rule. Write both orders as "sell down to 30," not "sell 30 points," and cancel one when the other fires. Otherwise a stop that fills at 222 and a close order an hour later can sell the same slice twice.

On the rebuild, your 3% to 266 against 6% of risk is fair for the first resistance level. But the first third is about ten points, so a failure costs roughly 0.6 of a point and a run from 258 back to 293 earns about 1.3. The break-even hit rate is around 30%. You're also right that the summer V began with a record-volume washout near 190, and a flip from here won't have that. So the first third is a probe and the real money goes in on the hold. Skipping the probe entirely risks missing the first leg of a move that was 51% last time, and that costs more than 0.6 of a point.

On proceeds, I side with Neutral. The rule is not to recreate the factor, so the money shouldn't go into another high-beta, long-duration software name. But cash is a default, not a destination. If a caller can't say where the freed risk budget goes within a few weeks, they should recognize this was only risk reduction.

Last, read the 10-Q today. It's the cheapest information we have, and it answers three things. What was the $1.9B outflow? What sits in the roughly $126M between operating income growth and net income growth? And when did the Q3 report land? If it came in mid-September, as Adobe's calendar usually suggests but I haven't confirmed, then the slide from 293 to 231 already contains a reaction to this margin story. That shrinks what we gain by being right, which is another reason to trim and not exit. If the squeeze is acquisition noise, December can be 50 and the rebuild cap 80. If it's organic, December goes to 40.

So the plan, in percent of a full position, with every number a ceiling:

  • Sell about ten now and ten more into 244 to 246, landing at 75 to 80.
  • Go to 60 at 248 to 251.
  • Go to about 45 on a rejection under 250 after a test of 255 to 257.
  • Make one cut to about 30 on a sub-227 close at the 3:50 check, with a stop-market near 222 behind it.
  • Rebuild in thirds, capped at 75 to 80, with levels reset weekly. The probe comes on a daily flip with a close above both averages, the next third on a hold, and the last on weekly follow-through.
  • Go into December at 50 or less, or 40 if the filing says the squeeze is organic.
  • Run the formula on the weight actually held before the FOMC once the date is confirmed, before November 3 and before the print, and take the smaller number.
  • If you hold nothing, don't initiate.

The bold part of this call was never the direction. We're acting on a falsifiable thesis, staying in the stock while the weekly trend is up, and committing to buy back on a flip. The cost if we're wrong is a few points of position value, and the formula caps the tail at a number the caller picks.

FINAL TRANSACTION PROPOSAL: SELL